

Blood and blood components



Legal Notice for Standards

Canadian Standards Association (CSA) standards are developed through a consensus standards development process approved by the Standards Council of Canada. This process brings together volunteers representing varied viewpoints and interests to achieve consensus and develop a standard. Although CSA administers the process and establishes rules to promote fairness in achieving consensus, it does not independently test, evaluate, or verify the content of standards.

Disclaimer and exclusion of liability

This document is provided without any representations, warranties, or conditions of any kind, express or implied, including, without limitation, implied warranties or conditions concerning this document's fitness for a particular purpose or use, its merchantability, or its non-infringement of any third party's intellectual property rights. CSA does not warrant the accuracy, completeness, or currency of any of the information published in this document. CSA makes no representations or warranties regarding this document's compliance with any applicable statute, rule, or regulation.

IN NO EVENT SHALL CSA, ITS VOLUNTEERS, MEMBERS, SUBSIDIARIES, OR AFFILIATED COMPANIES, OR THEIR EMPLOYEES, DIRECTORS, OR OFFICERS, BE LIABLE FOR ANY DIRECT, INDIRECT, OR INCIDENTAL DAMAGES, INJURY, LOSS, COSTS, OR EXPENSES, HOWSOEVER CAUSED, INCLUDING BUT NOT LIMITED TO SPECIAL OR CONSEQUENTIAL DAMAGES, LOST REVENUE, BUSINESS INTERRUPTION, LOST OR DAMAGED DATA, OR ANY OTHER COMMERCIAL OR ECONOMIC LOSS, WHETHER BASED IN CONTRACT, TORT (INCLUDING NEGLIGENCE), OR ANY OTHER THEORY OF LIABILITY, ARISING OUT OF OR RESULTING FROM ACCESS TO OR POSSESSION OR USE OF THIS DOCUMENT, EVEN IF CSA HAS BEEN ADVISED OF THE POSSIBILITY OF SUCH DAMAGES, INJURY, LOSS, COSTS, OR EXPENSES.

In publishing and making this document available, CSA is not undertaking to render professional or other services for or on behalf of any person or entity or to perform any duty owed by any person or entity to another person or entity. The information in this document is directed to those who have the appropriate degree of experience to use and apply its contents, and CSA accepts no responsibility whatsoever arising in any way from any and all use of or reliance on the information contained in this document.

CSA is a private not-for-profit company that publishes voluntary standards and related documents. CSA has no power, nor does it undertake, to enforce compliance with the contents of the standards or other documents it publishes.

Intellectual property rights and ownership

As between CSA and the users of this document (whether it be in printed or electronic form), CSA is the owner, or the authorized licensee, of all works contained herein that are protected by copyright, all trade-marks (except as otherwise noted to the contrary), and all inventions and trade secrets that may be contained in this document, whether or not such inventions and trade secrets are protected by patents and applications for patents. Without limitation, the unauthorized use, modification, copying, or disclosure of this document may violate laws that protect CSA's and/or others' intellectual property and may give rise to a right in CSA and/or others to seek legal redress for such use, modification, copying, or disclosure. To the extent permitted by licence or by law, CSA reserves all intellectual property rights in this document.

Patent rights

Attention is drawn to the possibility that some of the elements of this standard may be the subject of patent rights. CSA shall not be held responsible for identifying any or all such patent rights. Users of this standard are expressly advised that determination of the validity of any such patent rights is entirely their own responsibility.

Authorized use of this document

This document is being provided by CSA for informational and non-commercial use only. The user of this document is authorized to do only the following:

If this document is in electronic form:

- load this document onto a computer for the sole purpose of reviewing it;
- search and browse this document; and
- print this document if it is in PDF format.

Limited copies of this document in print or paper form may be distributed only to persons who are authorized by CSA to have such copies, and only if this Legal Notice appears on each such copy.

In addition, users may not and may not permit others to

- alter this document in any way or remove this Legal Notice from the attached standard;
- sell this document without authorization from CSA; or
- make an electronic copy of this document.

If you do not agree with any of the terms and conditions contained in this Legal Notice, you may not load or use this document or make any copies of the contents hereof, and if you do make such copies, you are required to destroy them immediately. Use of this document constitutes your acceptance of the terms and conditions of this Legal Notice.



CANADIAN STANDARDS
ASSOCIATION

CSA Standards Update Service

Z902-09

November 2009

Title: *Blood and blood components*

Pagination: **115 pages** (x preliminary and 105 text), each dated **November 2009**

To register for e-mail notification about any updates to this publication

- go to **www.ShopCSA.ca**
- click on **E-mail Services** under **MY ACCOUNT**
- click on **CSA Standards Update Service**

The **List ID** that you will need to register for updates to this publication is **2020704**.

If you require assistance, please e-mail techsupport@csa.ca or call 416-747-2233.

Visit CSA's policy on privacy at www.csagroup.org/legal to find out how we protect your personal information.

Currently in preview, click buy full version

CSA Standard

Z902-09

Blood and blood components



**CANADIAN STANDARDS
ASSOCIATION**

®Registered trade-mark of Canadian Standards Association

*Published in November 2009 by Canadian Standards Association
A not-for-profit private sector organization
5060 Spectrum Way, Suite 100, Mississauga, Ontario, Canada L4W 5N6
1-800-463-6727 • 416-747-4044*

Visit our Online Store at www.ShopCSA.ca



The Canadian Standards Association (CSA) prints its publications on Rolland Enviro100, which contains 100% recycled post-consumer fibre, is EcoLogo and Processed Chlorine Free certified, and was manufactured using biogas energy.

To purchase CSA Standards and related publications, visit CSA's Online Store at www.ShopCSA.ca or call toll free 1-800-463-6727 or 416-747-4044.

ISBN 978-1-55491-297-1

Technical Editor: Jeffrey Kraegel

© Canadian Standards Association — 2009

All rights reserved. No part of this publication may be reproduced in any form whatsoever without the prior permission of the publisher.

Contents

Technical Committee on Blood and Blood Components *viii*

Preface *x*

0 Introduction 1

1 Scope 1

2 Reference publications 2

3 Definitions and abbreviations 3

3.1 Definitions 3

3.2 Abbreviations 10

4 General 11

4.1 Policies 11

4.2 Operating procedures 12

4.2.1 General 12

4.2.2 Development, approval, and distribution of operating procedures 12

4.2.3 Document control 13

4.2.4 Storage and retention 14

4.3 Personnel 14

4.3.1 General 14

4.3.2 Training 15

4.3.3 Competency assessment and proficiency testing 15

4.3.4 Records 16

4.3.5 Specific requirements for blood centres 16

4.3.6 Specific requirements for transfusion services 16

4.4 Transfusion committee 17

4.5 Health and safety 17

4.5.1 General 17

4.5.2 Biological safety 17

4.5.3 Chemical safety 18

4.5.4 Radiation safety 18

4.6 Quality system 18

4.6.1 General 18

4.6.2 Corrective action 19

4.6.3 Periodic review and audits 19

4.6.4 Contracted, subsidiary facilities, and mobile clinic sites 20

4.7 Process control 20

5 Donor selection for allogeneic blood collection 21

5.1 General 21

5.2 Criteria to protect the donor 22

5.2.1 General 22

5.2.2 Age 23

5.2.3 Weight 23

5.2.4 Donation interval 23

5.2.5 Blood pressure 23

5.2.6 Hemoglobin and hematocrit 23

5.2.7 Current or past medical illness 24

- 5.2.8 Pregnancy 24
- 5.3 Criteria to protect the recipient 24
 - 5.3.1 General 24
 - 5.3.2 Personal or family history of Creutzfeldt-Jakob disease (CJD) 25
 - 5.3.3 Travel to Europe or the United Kingdom since 1980 25
 - 5.3.4 Receipt of blood components or other human tissue 26
 - 5.3.5 Ingestion of medications that alter platelet function 26
 - 5.3.6 Immunizations and vaccinations 26
 - 5.3.7 Cancer 27
 - 5.3.8 Infectious diseases 27
 - 5.3.9 Presence of risk factors for transmissible diseases 27
 - 5.3.10 Malaria 28
 - 5.3.11 Other protozoan diseases 29

6 Collection of blood and blood components for transfusion 29

- 6.1 General 29
- 6.2 Collection procedure 29
- 6.3 Storage and transportation from collection site 30
 - 6.3.1 Storage 30
 - 6.3.2 Transportation 30
 - 6.3.3 Blood components prepared at the collection site 31
- 6.4 Therapeutic phlebotomy 31

7 Preparation of blood components 31

- 7.1 General 31
- 7.2 Open system 31
- 7.3 Sterile connecting device 32
- 7.4 Pre-storage leukoreduction 32
- 7.5 Red blood cell components 33
 - 7.5.1 Red blood cells 33
 - 7.5.2 Red blood cells – frozen 33
 - 7.5.3 Red blood cells – washed 34
 - 7.5.4 Red blood cells – IgA deficient 34
 - 7.5.5 Red blood cells – rejuvenated 35
 - 7.5.6 Red blood cells – low volume 35
- 7.6 Plasma components 35
 - 7.6.1 General 35
 - 7.6.2 Fresh frozen plasma and frozen plasma 35
 - 7.6.3 Cryoprecipitated AHF 36
 - 7.6.4 Cryoprecipitate 36
 - 7.6.5 Cryosupernatant plasma 37
- 7.7 Platelets and platelets-pheresis 37
- 7.8 Granulocytes 38
- 7.9 Source plasma 38
- 7.10 Recovered plasma 38
- 7.11 Pooled or mixed components 38
- 7.12 Irradiation of blood and blood components 38
- 7.13 Quality control of allogeneic blood components 39

8 Testing and labelling of blood and blood components 39

- 8.1 General 39
- 8.2 ABO and Rh groups 40
- 8.3 Tests for detecting clinically significant red cell antibodies 41
- 8.4 Tests intended to prevent disease transmission 41

8.5	Visual test	42
8.6	Labelling	43
8.6.1	General	43
8.6.2	Blood and blood component identification	44
8.6.3	Labelling at collection or preparation	44
8.6.4	Labelling prior to release into inventory at the blood centre	45
8.6.5	Special labelling requirements	45
8.6.6	Circular of information	45
9	Release, storage, packing, and transportation of blood and blood components	45
9.1	General	45
9.2	Release from the blood centre	46
9.3	Release of untested blood and blood components	46
9.4	Storage	47
9.5	Packing and transportation	48
9.5.1	General	48
9.5.2	Facility-to-facility	48
9.5.3	Within a facility	49
10	Requests, pre-transfusion testing, selection of components, and acceptance criteria	49
10.1	General	49
10.2	Requests	50
10.3	Recipient blood samples	50
10.4	Testing of recipient blood	51
10.5	Testing of donor blood	52
10.6	Crossmatching	52
10.6.1	General	52
10.6.2	Serological crossmatch	52
10.6.3	Computer crossmatch	52
10.7	Selection of blood components	53
10.8	Pooled or mixed components	54
10.9	Special circumstances	54
10.9.1	Infants under 4 months	54
10.9.2	Massive transfusion	55
10.9.3	Emergency transfusion	56
10.10	Acceptability	56
11	Transfusion of blood and blood components	57
11.1	Conditions of transfusion	57
11.1.1	General	57
11.1.2	Records system	57
11.2	Information to recipients, including informed consent	58
11.3	Identification of recipient	58
11.4	Transfusion	59
11.5	Warming	60
11.6	Cellular blood components selected or processed to reduce the risk of CMV transmission	60
11.7	Irradiated blood and blood components	61
11.8	Granulocytes	61
11.9	Rh-immune globulin	61
12	Autologous blood collection and transfusion	62
12.1	General	62
12.2	Criteria for donation	63
12.3	Testing and labelling	63

- 12.3.1 Testing 63
- 12.3.2 Labelling 64
- 12.4 Pre-transfusion testing and transfusion 64
- 12.5 Perioperative collection 64
- 13 Apheresis donation 66**
 - 13.1 General 66
 - 13.2 Collection 67
 - 13.3 Additional requirements for each type of component collected 68
 - 13.3.1 Plasma collected by apheresis 68
 - 13.3.2 Platelets collected by apheresis 70
 - 13.3.3 Red blood cells collected by apheresis 70
 - 13.3.4 Leukocytes collected by apheresis 71
 - 13.4 Therapeutic apheresis 71
- 14 Transfusion service responsibilities regarding blood products used in the facility 71**
 - 14.1 General 71
 - 14.2 Records 72
 - 14.3 Requests 72
 - 14.4 Preparation for administration 72
 - 14.5 Administration 72
 - 14.6 Storage and transportation 72
 - 14.7 Home administration 73
 - 14.8 Adverse events 73
- 15 Directed donations and designated donations 73**
 - 15.1 Directed donations 73
 - 15.2 Designated donations 74
- 16 Walking donor programs 75**
 - 16.1 General 75
 - 16.2 Health care facility 75
 - 16.3 Donors 75
 - 16.4 Staff 76
 - 16.5 Labelling 76
 - 16.6 Testing 76
- 17 Home transfusion 77**
 - 17.1 General 77
 - 17.2 Recipient selection 77
 - 17.3 Informed consent 78
 - 17.4 Pre-transfusion testing and selection of components 78
 - 17.5 Transportation 78
 - 17.6 Administration 78
 - 17.7 Disposal of biohazardous waste 78
- 18 Adverse events 78**
 - 18.1 General 78
 - 18.2 Identifying, evaluating, and reporting 79
 - 18.3 Suspected hemolytic transfusion reactions 80
 - 18.4 Suspected bacterial sepsis 80
 - 18.5 Traceback in response to other transfusion-transmissible infections 81

19 Removal of unsafe components and donors from the blood supply 81

- 19.1 Post-donation information 81
- 19.2 Recall of allogeneic donations found positive for transmissible disease agents 82
- 19.3 Lookback 83
- 19.4 Recall procedure 84

20 Record management 84

- 20.1 General 84
- 20.2 Blood donation 86
- 20.3 Blood component processing 87
- 20.4 Final product 87
- 20.5 Distribution 87
- 20.6 Storage, retention, and archiving 87
 - 20.6.1 General 87
 - 20.6.2 Records of donors and donor blood components 87
 - 20.6.3 Records of recipients 88
 - 20.6.4 Other records 88
- 20.7 Product complaints, recalls, and corrective action 89

21 Computer systems 89

- 21.1 General 89
- 21.2 Computer system description and documentation 90
- 21.3 Computer system validation and periodic testing 90
- 21.4 Change control 91
- 21.5 Staff qualification 91
- 21.6 Records 91

22 Buildings and facilities 92

- 22.1 General 92
- 22.2 Blood component processing and testing areas 93
- 22.3 Sanitation program 93
- 22.4 Mobile sites 94
- 22.5 Receipt and storage of incoming goods, supplies, and materials 94

23 Mechanical equipment 94

- 23.1 General 94
- 23.2 New equipment 95
- 23.3 Calibration and performance verification 95
- 23.4 Maintenance 95
- 23.5 Repairs 96

Annexes

- A** (informative) — Bibliography 105

Tables

- 1** — Vaccination deferral period 96
- 2** — Blood and blood component storage, transportation, and expiration 97
- 3** — Allogeneic blood component quality control in manufacturing process 100
- 4** — Record retention requirements 104

Technical Committee on Blood and Blood Components

G. Delage	Héma-Québec, Saint-Laurent, Québec	<i>Chair</i>
J.L. Freedman	St. Michael's Hospital, Toronto, Ontario	<i>Vice-Chair</i>
F. Agbanyo	Blood, Tissues, Organs and Xenografts Division, Centre for Biologics Evaluation, Ottawa, Ontario	<i>Associate</i>
R. Berger	Blood Advisory Group, Niagara Falls, Ontario	
H. Dunlop	Blood, Tissues, Organs and Vaccines Division, Office of Regulatory Affairs, Ottawa, Ontario	<i>Associate</i>
N. Garneau	Ministère de la Santé et des Services Sociaux, Québec, Québec	
M. Hamilton	Department of Health Acute and Tertiary Care, <i>Representing CBS — P/T Blood Liaison Committee</i>	
N. Heddle	Transfusion Research Program McMaster University, Hamilton, Ontario <i>Representing CBS — P/T Blood Liaison Committee</i>	
H. Hume	Canadian Blood Services, Ottawa, Ontario	
C. Hyson	Blood Safety Surveillance and Health Care Acquired Infections Division, Centre for Communicable Diseases and Infection Control, Ottawa, Ontario	<i>Associate</i>
D. Lepine	Medical Devices Bureau In Vitro Diagnostic Devices, Ottawa, Ontario	<i>Associate</i>
J. Lobo-Dale	Office of Policy and International Collaboration, Ottawa, Ontario	<i>Associate</i>
A. Maguire	Canadian Society for Transfusion Medicine, Kamloops, British Columbia <i>Representing Canadian Society for Transfusion Medicine</i>	
G. Nayeri	BTOX Compliance Unit, Compliance, Enforcement and Coordination Division, Ottawa, Ontario	

S. O'Brien	Canadian Blood Services, Ottawa, Ontario	
D. Page	Canadian Hemophilia Society, La Durantaye, Québec	
G. Polnicky	Blood, Tissues, Organs and Xenografts Division Centre for Biologics Evaluation, Ottawa, Ontario	
S. Rémy	Héma-Québec, Saint-Laurent, Québec	
K. Robinson	Marketed Biologicals, Biotechnology and Natural Health Products Bureau, Ottawa, Ontario	<i>Associate</i>
G. Rock	Canadian Hematology Society, Ottawa, Ontario	
M. Silva	American Association of Blood Banks, Encino, California, USA	<i>Associate</i>
L. Stevens	Neutropenia Support Association, Winnipeg, Manitoba	
M. Tang	Office of Policy and International Collaboration, Ottawa, Ontario	<i>Associate</i>
M. Tremblay	Héma-Québec, Saint-Laurent, Québec	
T. Walker	Canadian Blood Services, Ottawa, Ontario	
J. Kraegel	Canadian Standards Association, Mississauga, Ontario	<i>Project Manager</i>

Preface

This is the second edition of CSA Z902, *Blood and blood components*. It supersedes the first edition, published in 2004.

This Standard was prepared by the Technical Committee on Blood and Blood Components, under the jurisdiction of the Strategic Steering Committee on Health Care Technology, and has been formally approved by the Technical Committee. This Standard has been approved as a National Standard of Canada by the Standards Council of Canada.

November 2009

Notes:

- (1) Use of the singular does not exclude the plural (and vice versa) when the sense allows.
- (2) Although the intended primary application of this Standard is stated in its Scope, it is important to note that it remains the responsibility of the users of the Standard to judge its suitability for their particular purpose.
- (3) This publication was developed by consensus, which is defined by CSA Policy governing standardization — Code of good practice for standardization as “substantial agreement. Consensus implies much more than a simple majority, but not necessarily unanimity”. It is consistent with this definition that a member may be included in the Technical Committee list and yet not be in full agreement with all clauses of this publication.
- (4) CSA Standards are subject to periodic review, and suggestions for their improvement will be referred to the appropriate committee.
- (5) All enquiries regarding this Standard, including requests for interpretation, should be addressed to Canadian Standards Association, 5060 Spectrum Way, Suite 100, Mississauga, Ontario, Canada L4W 5N6.
Requests for interpretation should
 - (a) define the problem, making reference to the specific clause, and, where appropriate, include an illustrative sketch;
 - (b) provide an explanation of circumstances surrounding the actual field condition; and
 - (c) be phrased where possible to permit a specific “yes” or “no” answer.

Committee interpretations are processed in accordance with the CSA Directives and guidelines governing standardization and are published in CSA's periodical Info Update, which is available on the CSA Web site at www.csa.ca.

Z902-09

Blood and blood components

0 Introduction

This Standard has been prepared to maintain and enhance the safety, efficacy, and quality of blood collection, storage, processing, and transfusion. The requirements set out in this Standard are the minimum criteria for acceptable performance and may be exceeded in practice. It should be noted that activities covered within this Standard can also be subject to federal, provincial, territorial, or local laws and regulations.

This Standard is not intended to replace detailed specifications and operating procedures; rather, the principles and criteria outlined in this Standard should be used in maintaining and preparing specifications and operating procedures.

Throughout this Standard, the term “blood component” refers to a therapeutic component of blood intended for transfusion (e.g., red cells, granulocytes, platelets, plasma) that can be prepared using conventional blood bank methodology. Such methods may include centrifugation, filtration, or freezing. The term “blood and blood components” comprises whole blood along with blood components, as described in this paragraph.

This Standard was developed by a balanced Technical Committee that includes health care professionals as well as representatives of the federal, provincial, and territorial governments, user groups, and blood centres. In developing this Standard, the Technical Committee extensively consulted equivalent standards in Canada and other jurisdictions, including the American Association of Blood Banks’ *Standards for Blood Banks and Transfusion Services* and the Canadian Society for Transfusion Medicine’s *Standards for Hospital Transfusion Services*. Differences from these standards, where they occur, represent the Technical Committee’s decisions based on Canadian practice and current scientific knowledge.

1 Scope

1.1

This Standard provides management requirements for facilities that collect, process, store, and use human blood and blood components for transfusion. It addresses issues of safety, efficacy, and quality for recipients, safety of donors, management of blood and blood components, and safety of facility personnel and others who are exposed to or potentially affected by blood and blood components.

1.2

This Standard applies to blood centres and transfusion services and to any other organization that collects, processes, stores, or uses human blood or blood components for transfusion.

1.3

As a management standard, this Standard is not intended to replace detailed specifications and operating procedures; rather, it is intended for use in their preparation. It includes requirements for policies and procedures, quality management, personnel, physical plant, and equipment. In addition, this Standard outlines specific requirements to be included in the facility’s operating procedures for the following activities:

- (a) donor selection for allogeneic blood collection;
- (b) collection of blood and blood components for transfusion;
- (c) preparation of blood components;
- (d) testing and labelling of blood and blood components;

- (e) release, storage, packing, and transportation;
- (f) requests, pre-transfusion testing, selection of components, and acceptance criteria;
- (g) transfusion;
- (h) autologous blood collection and transfusion;
- (i) apheresis donation;
- (j) transfusion service responsibilities regarding blood products used in the facility;
- (k) directed donations and designated donations;
- (l) walking donor programs;
- (m) home transfusion;
- (n) adverse event monitoring and corrective action;
- (o) removal of unsafe components and donors from the blood supply;
- (p) record management; and
- (q) validation and maintenance of computer systems.

1.4

This Standard does not include requirements for activities associated with

- (a) the collection of source plasma; and
- (b) the processing, manufacture, or commercial distribution of plasma derivatives and related blood products, including solvent detergent plasma.

Note: *Source plasma is covered under the Food and Drug Regulations for human plasma collected by plasmapheresis (i.e., Sections C.04.400 through C.04.423, Division 4, Part C).*

1.5

In CSA Standards, “shall” is used to express a requirement, i.e., a provision that the user is obliged to satisfy in order to comply with the standard; “should” is used to express a recommendation or that which is advised but not required; and “may” is used to express an option or that which is permissible within the limits of the standard. Notes accompanying clauses do not include requirements or alternative requirements; the purpose of a note accompanying a clause is to separate from the text explanatory or informative material. Notes to tables and figures are considered part of the table or figure and may be written as requirements. Annexes are designated normative (mandatory) or informative (non-mandatory) to define their application.

2 Reference publications

Note: *A bibliography is provided in Annex A.*

This Standard refers to the following publications, and where such reference is made, it shall be to the edition listed below, including all amendments published thereto.

CSA (Canadian Standards Association)

CAN/CSA-C22.2 No. 60601-1-08

Medical electrical equipment — Part 1: General requirements for basic safety and essential performance

Z317.10-09

Handling of waste materials in health care facilities and veterinary health care facilities

Government of Canada

Food and Drugs Act, Chapter F-27 of the Revised Statutes of Canada, 1985

Food and Drugs Regulations, Chapter 870 of the Consolidated Regulations of Canada, 1978

Part C (Drugs), Division 1A, Establishment Licensing